الفهرس 
Anticancer potential of tetra halo ruthenate nanocomposites on different human cancer cell lines
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 105 |  |  |
| | | from | 105 | | |
Abstract
Background: Chemotherapy is the most common cancer treatment, and metallic anticancer compounds have generated increasing amounts of interest since the discovery of cisplatin. More recently, scientists have focused on ruthenium-based compounds as an alternative for the platinum compounds. Which seems as idyllic candidates for study therapeutic anticancer alternatives to platinum derivatives, generally associated with low systemic toxicity than cisplatin. Aim of the study: To assess whether one or more of three Ruthenium-based nanocomposites, namely Ru+Lysine+CTAB (RCTL), Ru+Lysine (RL) and Ru+CTAB (RCT) exhibit pronounced anti-proliferative properties against cancer cells Material and Methods: The three Ruthenium-based nanocomposites characterized by Infra-Red Spectra, ultraviolet spectra and transmission electro microscopy to test them on different human cancer cell lines including MCF7, HepG2, A549 and PC3 versus normal human skin cell line (BJ1), Cytotoxic effect has been validated by MTT assay, also the molecular underlying mechanism of cytotoxicity has been tested via qRT-PCR for pro-apoptotic makers P53 and Casp3 and anti-apoptotic marker Bcl-2 as well as cell cycle analysis by flow cytometry. Results: Among the 3 nanocomposites RCTL gave the highest cytotoxicity especially on HepG2 with IC50 0.55 og/ml, but was still toxic on normal cell line with dose < 12.5 og/ml. RCTL and RCT nanocomposites have demonstrated a significant increase in the expression of P53 and Casp-3 markers versus untreated controls, but a significant reduction in the expression of Bcl-2. There was a direct correlation between the cytotoxic effect and the degree of apoptosis in the different cancer cell lines.The present study has also proved cell cycle arrest at G2/M phase in HepG2 and MCF7, A549 and PC3